Biosimilars Market - By Product (Insulin, Monoclonal Antibodies, Recombinant Human Growth Hormone (Rhgh), Granulocyte Colony-Stimulating Factor, Interferon, Erythropoietin, Etanercept, Follitropin, Glucagon, Calcitonin, And Teriparatide And Enoxaparin Sodium), By Type of Manufacturing (In-House Manufacturing, Contract Manufacturing), By Indication (Offsite Treatment, Oncology, Chronic Disorder, Autoimmune Disease, Blood Disorders, Infectious Disease, Other Diseases) And By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 193
Status: Published
Report Code: ARI100411
Rising prevalence of chronic diseases across the globe, especially in developing regions owing to rise in sedentary lifestyle and increasing habit of fast-food consumption will result in growing number of people suffering from such diseases. Hence, prevalence rate in developed as well as in certain areas in developing nations will augment the demand and adoption rate of biosimilar drugs, fuelling the business growth.
However, high development cost of the biosimilar drug will be one of the major reasons impeding the adoption rates in under-developed and few developing countries. As per a recent research, it takes around 7 to 8 years and costs around USD 100 million to USD 250 million to develop a biosimilar. High cost related to biosimilar drugs development will continue to hinder market growth over the forecast timeframe.
Since the oncology segment is likely to witness aggressive growth during the forecast period, companies in the biosimilars market are increasing efforts to introduce improved formulations of biologic products. Apart from biosimilars, companies are increasing the production of epoetin’s and filgrastim’s for the treatment of chemotherapy-induced neutropenia. Healthcare companies are also developing biosimilars to Rituximab, since the novel drug is FDA-approved. Biologic drugs similar to Rituximab are creating incremental opportunities for companies, as these drugs are being increasingly used in the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
The prominent players operating in biosimilars market include Pfizer (US), Sandoz (Germany), Biocon (India), Biogen (US), Fresenius Kabi AG (Germany), Boehringer Ingelheim (Germany), Merck KgaA (Germany), Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy's Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany).
Sandoz (Germany) is one of the leading players in the biosimilars market in 2019. The company boasts of a broad product portfolio across the globe. Over the years, the company has maintained its leading position in the biosimilars market.
Analyst Commentary
The biosimilars market is expected to expand at a high CAGR during the forecast period. Manufacturers are gaining business stability by increasingly innovating in biosimilars catering to cancer patients and are driving down costs of medicines.
One of the biggest barriers in the growth of orphan biosimilars is the long clinical development pathway due to evidence requirements for rare disease drugs. Hence, manufacturers are focusing on analytical similarity with originators to develop approval-worthy biosimilars. Companies should invest in developing economies of Asia Pacific such as India, since the country is an emerging hub for biologics and biosimilars. India’s biopharma sector is aiming to emulate the global standard in generic drugs and is increasing efforts to improve access to affordable biosimilar products.
Based on the product, the monoclonal antibody segment accounted for the largest market share in 2019. This is attributed primarily to the rising incidence of cancer and the increasing number of products launches/approvals. Based on the monoclonal antibody, the infliximab segment accounted for the largest biosimilars market share in 2019. The growing prevalence of autoimmune diseases drives the market growth.
Segmentation
The global biosimilars market is bifurcated based on the product, type of manufacturing, by indication and region. Based on the product, the biosimilars market industry is segmented into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, and teriparatide and enoxaparin sodium. Based on the monoclonal antibody, the biosimilars market industry is further segmented into infliximab, rituximab, trastuzumab, adalimumab, and other monoclonal antibodies. Based on type of manufacturing the market is bifurcated into In-House Manufacturing, Contract Manufacturing. Based on indication the market is bifurcated into Offsite Treatment, Oncology, Chronic Disorder, Autoimmune Disease, Blood Disorders, Infectious Disease, Other Diseases.
Regional Analysis
Europe has held the largest market share in terms of revenue due to the presence of a well-defined regulatory framework for biosimilars and major biopharmaceutical companies such as Johnson & Johnson, Novartis, AstraZeneca, Pfizer, Merck, Sanofi, and GlaxoSmithKline. Furthermore, well-developed healthcare infrastructure and a growing number of product launches have fueled the regional market growth.
Europe was followed by Asia Pacific, which accounted for a major market share. Growing demand for less expensive therapeutic products and a high prevalence of chronic diseases in Asia Pacific are contributing to the regional market growth. Increasing focus on product developments in countries including China, India, and South Korea is another major factor market driver.
North America is projected to exhibit high CAGR during the forecast period, due to rising efforts from manufacturers to tap growth opportunities in the U.S. and Canada. The U.S. biosimilar regulatory pathway was established in March 2009, and since then the region has gained significant momentum, presenting new opportunities and challenges. U.S. FDA approved the first biosimilar product, Zarxio (filgrastim-sndz), in March 2015.
TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data Products
2.3.1. Secondary Products
2.3.1.1. Preliminary data mining
2.3.2. Primary Products
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Global Biosimilars Market
Chapter 5. Global Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
5.1. Global Biosimilars Market Share, By Product, 2015 - 2027 (USD Million)
5.1.1. Insulin
5.1.1.1. Market Size and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. Monoclonal Antibodies
5.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. Recombinant Human Growth Hormone
5.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.4. Granulocyte Colony-Stimulating Factor
5.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.5. Interferon
5.1.5.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.5.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.6. Itanercept
5.1.6.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.6.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.7. Follitropin
5.1.7.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.7.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.8. Glucagon
5.1.8.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.8.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.9. Calcitonin
5.1.9.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.9.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.10. Teriparatide
5.1.10.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.10.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.11. Enoxaparin Sodium
5.1.11.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.11.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
6.1. Global Biosimilars Share, By Type of Manufacturing, 2015 - 2027 (USD Million)
6.1.1. In-House Manufacturing
6.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Contract Manufacturing
6.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Biosimilars Market Overview, By Indication, 2015 - 2027 (USD Million)
7.1. Global Biosimilars Share, By Indication, 2015 - 2027 (USD Million)
7.1.1. Offsite Treatment
7.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.2. Oncology
7.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.3. Chronic Disorder
7.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.4. Other Disease
7.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.5. Blood Disorders
7.1.5.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.5.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.6. Infectious Disease
7.1.6.1. Market Size and Projections, 2015 - 2027 (USD Million)
7.1.6.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 8. Global Biosimilars Market Overview, By Geography, 2015 – 2027 (USD Million)
8.1. Global Biosimilars Market Share, By Geography, 2015 - 2027 (USD Million)
8.1.1. Market Size and projections, by Countries, 2015 – 2027 (USD Million)
8.1.2. Market Share and CAGR Comparison, by Countries, 2019 (%)
Chapter 9. North America Biosimilars Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1. North America Global Biosimilars Market Overview, 2015 - 2027 (USD Million)
9.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.2. North America Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
9.1.3. North America Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
9.1.4. North America Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
9.1.5. North America Biosimilars Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.5.1. U.S. Biosimilars Market Overview, 2015 - 2027 (USD Million)
9.1.5.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.5.1.2. U.S. Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
9.1.5.1.3. U.S. Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
9.1.5.1.4. U.S. Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
9.1.5.2. Canada Biosimilars Market Overview, 2015 - 2027 (USD Million)
9.1.5.2.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.5.2.2. Canada Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
9.1.5.2.3. Canada Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
9.1.5.2.4. Canada Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
9.1.5.3. Mexico Biosimilars Market Overview, 2015 - 2027 (USD Million)
9.1.5.3.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.5.3.2. Mexico Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
9.1.5.3.3. Mexico Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
9.1.5.3.4. Mexico Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
Chapter 10. Europe Biosimilars Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1. Europe Biosimilars Market Overview, 2015 – 2027 (USD Million)
10.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.2. Europe Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
10.1.3. Europe Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
10.1.4. Europe Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
10.1.5. Europe Biosimilars Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.5.1. Germany
10.1.5.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.5.1.2. Germany Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
10.1.5.1.3. Germany Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
10.1.5.1.4. Germany Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
10.1.5.2. France
10.1.5.2.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.5.2.2. France Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
10.1.5.2.3. France Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
10.1.5.2.4. France Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
10.1.5.3. UK
10.1.5.3.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.5.3.2. UK Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
10.1.5.3.3. UK Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
10.1.5.3.4. UK Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
10.1.5.4. Italy
10.1.5.4.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.5.4.2. Italy Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
10.1.5.4.3. Italy Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
10.1.5.4.4. Italy Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
10.1.5.5. Spain
10.1.5.5.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.5.5.2. Spain Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
10.1.5.5.3. Spain Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
10.1.5.5.4. Spain Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
10.1.5.6. Rest of Europe
10.1.5.6.1. Market size and projections, 2015 – 2025
10.1.5.6.2. Rest of Europe Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
10.1.5.6.3. Rest of Europe Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
10.1.5.6.4. Rest of Europe Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
Chapter 11. Asia Pacific Biosimilars Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Asia Pacific Biosimilars Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.2. Asia Pacific Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
11.1.3. Asia Pacific Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
11.1.4. Asia Pacific Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
11.1.5. Asia Pacific Biosimilars Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.5.1. India
11.1.5.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.5.1.2. India Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
11.1.5.1.3. India Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
11.1.5.1.4. India Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
11.1.5.2. China
11.1.5.2.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.5.2.2. China Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
11.1.5.2.3. China Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
11.1.5.2.4. China Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
11.1.5.3. Japan
11.1.5.3.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.5.3.2. Japan Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
11.1.5.3.3. Japan Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
11.1.5.3.4. Japan Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
11.1.5.4. South Korea
11.1.5.4.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.5.4.2. South Korea Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
11.1.5.4.3. South Korea Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
11.1.5.4.4. South Korea Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
11.1.5.5. Rest of Asia Pacific
11.1.5.5.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.5.5.2. Rest of Asia Pacific Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
11.1.5.5.3. Rest of Asia Pacific Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
11.1.5.5.4. Rest of Asia Pacific Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
Chapter 12. Middle East & Africa Global Biosimilars Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. Middle East & Africa Biosimilars Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.2. Middle East & Africa Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
12.1.3. Middle East & Africa Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
12.1.4. Middle East & Africa Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
12.1.5. Middle East & Africa Biosimilars Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1.5.1. GCC
12.1.5.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.5.1.2. GCC Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
12.1.5.1.3. GCC Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
12.1.5.1.4. GCC Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
12.1.5.2. South Africa
12.1.5.2.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.5.2.2. South Africa Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
12.1.5.2.3. South Africa Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
12.1.5.2.4. South Africa Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
12.1.5.3. Rest of Middle East & Africa
12.1.5.3.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.5.3.2. Rest of Middle East & Africa Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
12.1.5.3.3. Rest of Middle East & Africa Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
12.1.5.3.4. Rest of Middle East & Africa Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
Chapter 13. South America Global Biosimilars Market Overview, By Countries, 2015 - 2027 (USD Million)
13.1. South America Biosimilars Market Overview, 2015 - 2027 (USD Million)
13.1.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.2. South America Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
13.1.3. South America Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
13.1.4. South America Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
13.1.5. South America Biosimilars Market Overview, By Countries, 2015- 2026 (USD Million)
13.1.5.1. Brazil
13.1.5.1.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.5.1.2. Brazil Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
13.1.5.1.3. Brazil Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
13.1.5.1.4. Brazil Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
13.1.5.2. Argentina
13.1.5.2.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.5.2.2. Argentina Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
13.1.5.2.3. Argentina Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
13.1.5.2.4. Argentina Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
13.1.5.3. Rest of South America
13.1.5.3.1. Market size and projections, 2015 – 2026
13.1.5.3.2. Rest of South America Biosimilars Market Overview, By Product, 2015 - 2027 (USD Million)
13.1.5.3.3. Rest of South America Biosimilars Market Overview, By Type of Manufacturing, 2015 - 2027 (USD Million)
13.1.5.3.4. Rest of South America Biosimilars Market Overview, By End Use, 2015 - 2027 (USD Million)
Chapter 14. Competitive Landscape
14.1. Competitive environment, 2020
14.2. Strategic framework
14.2.1. Partnership/agreement
14.2.2. Expansion
14.2.3. Mergers & Acquisitions
14.2.4. New Product & In-House Manufacturing
Chapter 15. Key Player Analysis
15.1. Pfizer
15.1.1. Company overview
15.1.2. Financial performance
15.1.3. Product & In-House Manufacturing Benchmarking
15.1.4. Recent initiatives
15.1.5. SWOT analysis
15.2. Sandoz
15.2.1. Company overview
15.2.2. Financial performance
15.2.3. Product & In-House Manufacturing Benchmarking
15.2.4. Recent initiatives
15.2.5. SWOT analysis
15.3. Biocon
15.4. Biogen
15.5. Fresenius Kabi AG
15.6. Boehringer Ingelheim
15.7. Merck KgaA
15.8. Mylan
15.9. Eli Lily
15.10. Teva Pharmaceuticals
Chapter 16. Global Biosimilars Market Cost Analysis
16.1. Global Biosimilars Market Key Raw Product Analysis
16.1.1. Key Raw Product
16.1.2. NEUROLOGY Trend of Key Raw Product
16.1.3. Key Suppliers of Raw Product
16.1.4. Market Concentration Rate of Raw Product
16.2. Proportion of Wing Cost Structure
16.2.1. Raw Product
16.2.2. Labor Cost
16.2.3. Wing Expenses
16.3. Wing Process Analysis of Unsaturated Polyester Resin (UPR) for Composites
Chapter 17. Chain, Sourcing Strategy and Downstream Buyers
17.1. Global Biosimilars Market Chain Analysis
17.2. Upstream Raw Product Sourcing
17.3. Raw Product of Global Biosimilars Market Major Manufacturers in 2019
17.4. Downstream Buyers
Chapter 18. Marketing Strategy Analysis, Distributors/Traders
18.1. Marketing Channel
18.1.1. Direct Marketing
18.1.2. Indirect Marketing
18.1.3. Marketing Channel Development Trend
18.2. Market Positioning
18.2.1. Pricing Strategy
18.2.2. Brand Strategy
18.2.3. Target Electrical Damage
18.3. Distributors/Traders List
Chapter 19. Market Effect Factors Analysis
19.1. Product & In-House Manufacturing Progress/Risk
19.1.1. Substitutes Threat
19.1.2. Product & In-House Manufacturing Progress in Related Product
19.2. In-House Manufacturing Needs/Customer Preference Change
19.3. Economic/Political Environmental Change
Chapter 20. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Biosimilars Market share, by Product, 2020 & 2027 (%)
10. Global Biosimilars Market share, by Insulin, by Product, 2020 & 2027 (USD Million)
11. Global Biosimilars Market share, by Monoclonal Antibodies, by Product, 2020 & 2027 (USD Million)
12. Global Biosimilars Market share, by Recombinant Human Growth Hormone, by Product, 2020 & 2027 (USD Million)
13. Global Biosimilars Market share, by Granulocyte Colony-Stimulating Factor, by Product, 2020 & 2027 (USD Million)
14. Global Biosimilars Market share, by Product, 2020 & 2027 (%)
15. Global Biosimilars Market share, by Type of Manufacturing, 2020 & 2027 (%)
16. Global Biosimilars Market share, by In-House Manufacturing, by Type of Manufacturing, 2020 & 2027 (USD Million)
17. Global Biosimilars Market share, by Contract Manufacturing, by Type of Manufacturing, 2020 & 2027 (USD Million)
18. Global Biosimilars Market share, by Product, 2020 & 2027 (%)
19. Global Biosimilars Market share, by Insulin, by Product, 2020 & 2027 (USD Million)
20. Global Biosimilars Market share, by Monoclonal Antibodies, by Product, 2020 & 2027 (USD Million)
21. Global Biosimilars Market share, by Recombinant Human Growth Hormone, by Product, 2020 & 2027 (USD Million)
22. Global Biosimilars Market share, by Granulocyte Colony-Stimulating Factor, by Product, 2020 & 2027 (USD Million)
23. Global Biosimilars Market share, by End Use, 2020 & 2027 (%)
24. Global Biosimilars Market share, by Offsite Treatment, by End Use, 2020 & 2027 (USD Million)
25. Global Biosimilars Market share, by Oncology, by End Use, 2020 & 2027 (USD Million)
26. Global Biosimilars Market share, by Chronic Disorder, by End Use, 2020 & 2027 (USD Million)
27. Global Biosimilars Market share, by Other Disease, by End Use, 2020 & 2027 (USD Million)
28. Global Biosimilars Market share, by region, 2020 - 2027(%)
29. Global Biosimilars Market share, by region, 2019 - 2027(USD Million)
30. Global Biosimilars Market share, by Origins, 2020 & 2027 (%)
31. Global Biosimilars Market share, by Natural, by Origins, 2020 & 2027 (USD Million)
32. Global Biosimilars Market share, by Artificial, by Origins, 2020 & 2027 (USD Million)
33. Global Biosimilars Market share, by Nature-Identical, by Origins, 2020 & 2027 (USD Million)
34. North America Global Biosimilars Market, 2020 - 2027(USD Million)
35. North America Global Biosimilars Market share, by Countries, 2020 & 2027 (%)
36. U.S. Global Biosimilars Market, 2020 - 2027(USD Million)
37. Canada Global Biosimilars Market, 2020 - 2027(USD Million)
38. Europe Global Biosimilars Market, 2020 - 2027(USD Million)
39. Europe Global Biosimilars Market share, by Countries, 2020 & 2027 (%)
40. Spain Global Biosimilars Market, 2020 - 2027(USD Million)
41. UK Global Biosimilars Market, 2020 - 2027(USD Million)
42. Italy Global Biosimilars Market, 2020 - 2027(USD Million)
43. Germany Global Biosimilars Market, 2020 - 2027(USD Million)
44. France Global Biosimilars Market, 2020 - 2027(USD Million)
45. Rest of Europe Global Biosimilars Market, 2020 - 2027(USD Million)
46. Asia-Pacific Global Biosimilars Market, 2020 - 2027(USD Million)
47. Asia-Pacific Global Biosimilars Market share, by Countries, 2020 & 2027 (%)
48. China Global Biosimilars Market, 2020 - 2027(USD Million)
49. India Global Biosimilars Market, 2020 - 2027(USD Million)
50. Australia Global Biosimilars Market, 2020 - 2027(USD Million)
51. Japan Global Biosimilars Market, 2020 - 2027(USD Million)
52. Rest of Asia-Pacific Global Biosimilars Market, 2020 - 2027(USD Million)
53. Middle East & Africa Global Biosimilars Market, 2020 - 2027(USD Million)
54. Middle East & Africa Global Biosimilars Market share, by Countries, 2020 & 2027 (%)
55. GCC Global Biosimilars Market, 2020 - 2027(USD Million)
56. South Africa Global Biosimilars Market, 2020 - 2027(USD Million)
57. Rest of Middle East & Africa Global Biosimilars Market, 2020 - 2027(USD Million)
58. South America Global Biosimilars Market, 2020 - 2027(USD Million)
59. Brazil Global Biosimilars Market, 2020 - 2027(USD Million)
60. Mexico Global Biosimilars Market, 2020 - 2027(USD Million)
61. Argentina Global Biosimilars Market, 2020 - 2027(USD Million)
62. Rest Of South America Global Biosimilars Market, 2020 - 2027(USD Million)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Biosimilars Market, 2020-2027 (USD Million)
4. Biosimilars requirement, by country, 2020-2027, (USD Million)
5. North America Biosimilars Market, By Product, 2020-2027 (USD Million)
6. North America Biosimilars Market, by Type of Manufacturing, 2020-2027 (USD Million)
7. North America Biosimilars Market, by Product, 2020-2027 (USD Million)
8. Europe Biosimilars Market, By Product, 2020-2027 (USD Million)
9. Europe Biosimilars Market, by Type of Manufacturing, 2020-2027 (USD Million)
10. Europe Biosimilars Market, by Product, 2020-2027 (USD Million)
11. Asia Pacific Biosimilars Market, By Product, 2020-2027 (USD Million)
12. Asia Pacific Biosimilars Market, by Type of Manufacturing, 2020-2027 (USD Million)
13. Asia Pacific Biosimilars Market, by Product, 2020-2027 (USD Million)
14. Middle East & Africa Global Biosimilars Market, By Product, 2020-2027 (USD Million)
15. Middle East & Africa Biosimilars Market, by Type of Manufacturing, 2020-2027 (USD Million)
16. Middle East & Africa Biosimilars Market, by Product, 2020-2027 (USD Million)
17. South America Biosimilars Market, By Product, 2020-2027 (USD Million)
18. South America Biosimilars Market, by Type of Manufacturing, 2020-2027 (USD Million)
19. South America Biosimilars Market, by Product, 2020-2027 (USD Million)
20. Global Biosimilars Market, Company Market Share, 2018 (%)
21. Pfizer : Product Benchmarking
22. Pfizer : Financial Performance
23. Sandoz : Product Benchmarking
24. Sandoz : Financial Performance
25. Biocon : Product Benchmarking
26. Biocon : Financial Performance
27. Biogen : Product Benchmarking
28. Biogen : Financial Performance
29. Fresenius Kabi AG : Product Benchmarking
30. Fresenius Kabi AG : Financial Performance
31. Boehringer Ingelheim : Product Benchmarking
32. Boehringer Ingelheim : Financial Performance
33. Merck KgaA : Product Benchmarking
The Leading Key Players in Biosimilars Market
Pfizer (US)
Sandoz (Germany)
Biocon (India)
Biogen (US)
Fresenius Kabi AG (Germany)
Boehringer Ingelheim (Germany)
Merck KgaA (Germany)
Mylan (US)
Eli Lilly (US)
Teva Pharmaceutical (Israel)
Dr. Reddy's Laboratories (India)
Amgen (US)
Celltrion (South Korea)
Samsung Biologics (South Korea)
Amega Biotech (Argentina)
mAbxience (Switzerland)
Probiomed (Mexico)
Apotex (Canada)
Chong Kun Dang (South Korea)
JCR Pharmaceuticals (Japan)
Gan & Lee Pharmaceuticals (China)
Gedeon Richter (Hungary)
Biocad (Russia)
Coherus Bioscience (US)
Stada Arzneimittel AG (Germany).
